The Discovery Labs has signed a foundational lease with the University of Pennsylvania Gene Therapy Program (GTP), which will use Discovery Labs’ suburban campus for a portion of its expanding research operations focused on the development of genetic medicines for rare and orphan diseases, as well as acquired and pandemic infectious diseases, such as COVID-19.
The Discovery Labs’ 2.4 million square foot site in King of Prussia, PA provides all the necessary ingredients to accelerate speed to market for cell and gene therapy innovators. The Center for Breakthrough Medicines is a cell and gene therapy contract development and manufacturing organization (CDMO) for plasmid DNA, viral vectors, and cellular therapy products and is located on-site.
Philadelphia is not just the city of brotherly love. It is one of the nation’s top biopharma hubs and the birthplace of cell and gene therapy. Within the next few years, the role of life sciences companies and institutions that call the city home is expected to grow at an accelerated rate, further cementing the city’s place as a key biopharma ecosystem.
Joerg Ahlgrimm Appointed as President and COO of The Discovery Labs.
